enGene Holdings Inc. Files Material Definitive Agreement
Ticker: ENGNW · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1980845
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
enGene Holdings Inc. just signed a big deal, details to come.
AI Summary
On December 20, 2024, enGene Holdings Inc. filed an 8-K report detailing a material definitive agreement. The filing does not specify the nature of the agreement or any associated dollar amounts, but it indicates a significant event for the company.
Why It Matters
This filing signals a significant business development for enGene Holdings Inc., potentially impacting its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications for the company's future, but lacks specific details to fully assess the risk.
Key Players & Entities
- enGene Holdings Inc. (company) — Registrant
- December 20, 2024 (date) — Date of Report
- 514 332-4888 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement filed by enGene Holdings Inc. on December 20, 2024?
The filing does not specify the nature of the material definitive agreement.
Are there any financial terms or dollar amounts associated with the material definitive agreement?
The provided filing excerpt does not contain information on financial terms or dollar amounts related to the agreement.
What is the principal executive office address for enGene Holdings Inc.?
The principal executive offices are located at 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada, H4R 2P1.
What is the Commission File Number for enGene Holdings Inc.?
The Commission File Number for enGene Holdings Inc. is 001-41854.
When is enGene Holdings Inc.'s fiscal year end?
enGene Holdings Inc.'s fiscal year end is October 31.
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2024-12-20 06:59:28
Key Financial Figures
- $11.50 — e Common Share, at an exercise price of $11.50 per Share ENGNW The Nasdaq Stock Ma
- $100,000,000 — ng an aggregate offering price of up to $100,000,000. Upon delivery of an issuance notice
Filing Documents
- engn-20241220.htm (8-K) — 50KB
- engn-ex1_1.htm (EX-1.1) — 336KB
- engn-ex5_1.htm (EX-5.1) — 16KB
- img93391562_0.jpg (GRAPHIC) — 6KB
- img93391562_1.jpg (GRAPHIC) — 6KB
- img93391562_2.jpg (GRAPHIC) — 2KB
- 0000950170-24-138767.txt ( ) — 628KB
- engn-20241220.xsd (EX-101.SCH) — 45KB
- engn-20241220_htm.xml (XML) — 6KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 20, 2024, enGene Holdings Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Sale Agreement") with Jefferies LLC, as sales agent ("Jefferies"), pursuant to which the Company may offer and sell, from time to time, through Jefferies, the Company's common shares, without par value (the "Shares"). Pursuant to the prospectus supplement, dated December 20, 2024, the Company may offer and sell Shares having an aggregate offering price of up to $100,000,000. Upon delivery of an issuance notice and subject to the terms and conditions of the Sale Agreement, Jefferies will use commercially reasonable efforts consistent with its normal sales and trading practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Company's instructions, including any price, time or size limits specified by the Company. Under the Sale Agreement, Jefferies may sell the Shares by any method deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or any other method permitted by law. Pursuant to the Sale Agreement, no Shares will be offered or sold in Canada, or knowingly to a person resident in Canada. The Company will pay Jefferies a commission of up to 3.0% of the gross proceeds of Shares sold pursuant to the Sale Agreement, and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any Shares under the Sale Agreement. The offering of the Shares pursuant to the Sale Agreement will terminate upon the termination of the Sale Agreement by Jefferies or the Company, as permitted therein. Sales of the Shares under the Sale Agreement will be made pursuant to the registration statement on Form S-3 (F
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibits 1.1 Open Market Sale Agreement SM , dated December 20, 2024, by and between enGene Holdings Inc. and Jefferies LLC. 5.1 Opinion of Blake, Cassels & Graydon LLP. 23.1 Consent of Blake, Cassels & Graydon LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENGENE HOLDINGS INC. Date: December 20, 2024 By: /s/ Lee Giguere Name: Title: Lee Giguere Chief Legal Officer